ChemoCentryx now owns the drug’s rights, including for inflammatory bowel disease, thus ending the seven-year strategic alliance between the two companies. GSK initially paid $63.5 million to ChemoCentryx to study treatments for IBD.
Vercirnon failed to meet GSK’s primary and secondary endpoint in the first of four Phase III trials; the drug neither brought an improved clinical response nor clinical remission.
More Articles on Gastroenterology:
“S” or “C” Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
Colonoscopy Could Prevent 40% Colon Cancer Cases, Study Says
Gastro Florida Practice Names Mark O’Neill as CEO
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.